Showing results (1-10 of 217) with videos related to
Sort By:
Pageof 22
Human Pathology|March 26, 2005
Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelinesDavid G Hicks, Raymond R TubbsJournal of Molecular Histology|January 11, 2007
An approach to the validation of novel molecular markers of breast cancer via TMA-based FISH scanningRaymond R Tubbs, Eric Swain, James D Pettay, et al.Applied Immunohistochemistry & Molecular Morphology : AIMM|November 24, 2006
Automation of manual components and image quantification of direct dual label fluorescence in situ hybridization (FISH) for HER2 gene amplification: A feasibility studyRaymond R Tubbs, James D Pettay, Eric Swain, et al.The American Journal of Surgical Pathology|August 13, 2005
The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization studyErinn Downs-Kelly, Brian J Yoder, Mark Stoler, et al.International Journal of Fertility and Women'S Medicine|February 3, 2007
HER2 status in bilateral breast cancerJoseph P Crowe, Rebecca J Patrick, Lisa A Rybicki, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2005
The expression of fascin, an actin-bundling motility protein, correlates with hormone receptor-negative breast cancer and a more aggressive clinical courseBrian J Yoder, Elisa Tso, Marek Skacel, et al.Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B|October 22, 2008
Mutations in myeloid neoplasmsClaudiu V Cotta, Raymond R TubbsHuman Pathology|May 14, 2005
The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization studyDavid G Hicks, Brian J Yoder, James Pettay, et al.Plos One|August 26, 2014
Concomitant detection of HER2 protein and gene alterations by immunohistochemistry (IHC) and silver enhanced in situ hybridization (SISH) identifies HER2 positive breast cancer with and without gene amplificationZsuzsanna Varga, Raymond R Tubbs, Holger MochBreast (Edinburgh, Scotland)|May 24, 2006
A data model to predict HER2 status in breast cancer based on the clinical and pathologic profiles of a large patient population at a single institutionJoseph P Crowe, Rebecca J Patrick, Lisa A Rybicki, et al.Pageof 22